Sanofi-Aventis China R&D Head Frank Jiang On Fast And Furious Adaptation In China: An Interview With PharmAsia News (Part 2 of 2)

Sanofi-Aventis is grabbing a larger share of emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down with PharmAsia News to discuss the environment in China and how Sanofi is approaching R&D there. Jiang is also a member of the networking organization BayHelix, which links Chinese life sciences executives.